Aytu BioScience, Inc. (NASDAQ:AYTU) traded at $1.42 at last check on Tuesday, Jun 30, making a downturn move of -7.47% on its previous day’s price.
There have been no upward or downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the AYTU stock, short term indicators assign the stock an average of Hold, while medium term indicators assign it an average of 50% Buy. Long term indicators on average place the stock in the category of 100% Buy.
Based on estimates by 2 analysts where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, none have rated the Aytu BioScience, Inc. (AYTU) stock as a Hold, while 2 rate it as a Buy. None analysts rate it as outperform while none of them rated it as underperform, whereas none suggests the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note that the PEG ratio for the AYTU stock currently stands at 0, and the current price level is -4.75% off its SMA20 and -5.98% from its 50-day simple moving average. The RSI (14) is pointing at 43.62 while the volatility over the past week is 5.56% and drops to 5.25% over the past one month. The beta value is 0.36, while the average true range (ATR) is currently pointing at 0.09. The average price target for the stock over the next 12 months is $2.75, with the estimates having a low of $2.5 and a high of $3. These price ends are 76.06% and +111.27% off the current price level respectively, although investors could be excited at the prospect of a +93.66% if the AYTU share price touches on the median price of $2.75.
Let’s briefly compare Aytu (AYTU) stock to its peers. We find that today’s price change of -7.47% and -18.52% over the past 12 months for AYTU competes that of Amgen Inc (AMGN), which has seen its stock price rise 0.62% in the latest trading session and is +25.66% over the last one year. Another of its peers Gilead Sciences Inc (GILD) has climbed 2.09% today, and is +10.36% up over the past year, while Vertex Pharmaceutic (VRTX) is also down -7.47% yet its price remains in the red at -18.52% over the same period. Amgen has a P/E ratio of 18.14 compared to Aytu’s 0 and Gilead’s 19.17. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at 0.04% and 0.46%, respectively, in early deals.